产品
编 号：F096379
分子式：C21H25Na2O10P
分子量：514.37
分子式：C21H25Na2O10P
分子量：514.37
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1254702-87-8
产品详情
生物活性：
Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide promotes apoptosis.
体内研究：
Minnelide (injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily) leads to a marked decrease in tumor weight and volume at the end of treatment and increases survival in orthotopic model of pancreatic cancer with MIA PaCa-2–derived human pancreatic tumors.Minnelide (injection intraperitoneally; 0.42 mg/kg; once daily; 28 days) prevents locoregional spread and leads to a decrease in average tumor weight in a xenograft model of pancreatic cancer with metastatic S2-013 cells.Minnelide (injection intraperitoneally; 0.42 mg/kg, 0.21 mg/kg; once daily) causes tumor regression and tumors from Minnelide-treated animals showed fibrosis and the presence of pyknotic nuclei in human pancreatic cancer xenografts in SCID mice.Animal Model:Orthotopic model of pancreatic cancer with MIA PaCa 2-derived human pancreatic tumors in athymic nude mice
Dosage:0.1-0.6 mg/kg
Administration:Injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily
Result:Prevented pancreatic tumor growth in vivo.
Animal Model:Xenograft model of pancreatic cancer with metastatic S2-013 cell line in athymic nude mice
Dosage:0.42 mg/kg
Administration:Injection intraperitoneally; 0.42 mg/kg; once daily
Result:Prevented extensive spread from the primary site of injection.
Animal Model:Human pancreatic cancer xenograftsin SCID mice
Dosage:0.21 mg/kg, 0.42 mg/kg
Administration:Injection intraperitoneally; 0.42 mg/kg; once daily
Result:Reduced tumor burden in human xenografts from patients.
体外研究：
Minnelide (0-200 nM; 48 hours) shows significantly decreased cell viability in pancreatic cancer cell lines after treatment in the presence, but not in the absence, of phosphatase.
Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide promotes apoptosis.
体内研究：
Minnelide (injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily) leads to a marked decrease in tumor weight and volume at the end of treatment and increases survival in orthotopic model of pancreatic cancer with MIA PaCa-2–derived human pancreatic tumors.Minnelide (injection intraperitoneally; 0.42 mg/kg; once daily; 28 days) prevents locoregional spread and leads to a decrease in average tumor weight in a xenograft model of pancreatic cancer with metastatic S2-013 cells.Minnelide (injection intraperitoneally; 0.42 mg/kg, 0.21 mg/kg; once daily) causes tumor regression and tumors from Minnelide-treated animals showed fibrosis and the presence of pyknotic nuclei in human pancreatic cancer xenografts in SCID mice.Animal Model:Orthotopic model of pancreatic cancer with MIA PaCa 2-derived human pancreatic tumors in athymic nude mice
Dosage:0.1-0.6 mg/kg
Administration:Injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily
Result:Prevented pancreatic tumor growth in vivo.
Animal Model:Xenograft model of pancreatic cancer with metastatic S2-013 cell line in athymic nude mice
Dosage:0.42 mg/kg
Administration:Injection intraperitoneally; 0.42 mg/kg; once daily
Result:Prevented extensive spread from the primary site of injection.
Animal Model:Human pancreatic cancer xenograftsin SCID mice
Dosage:0.21 mg/kg, 0.42 mg/kg
Administration:Injection intraperitoneally; 0.42 mg/kg; once daily
Result:Reduced tumor burden in human xenografts from patients.
体外研究：
Minnelide (0-200 nM; 48 hours) shows significantly decreased cell viability in pancreatic cancer cell lines after treatment in the presence, but not in the absence, of phosphatase.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备